Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

A Prospective, Observational Study of Bleeding and Quality of Life in Patients with Glanzmann Thrombasthenia in the United Kingdom: Updated Results

2
November 2023

New insights from a prospective study on Glanzmann thrombasthenia (GT) have been published in Blood (2023).

View Articles

A Phase 1/2, First-in-Human, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

2
November 2023

Exciting findings from a Phase 1/2 first-in-human study on HMB-001 for Glanzmann thrombasthenia have been published in Blood (2023).

View Articles

Employee Well-Being: A Commitment that Defines Richmond

2
October 2023

Dr. Junko Ono, the Occupational Support Manager at Richmond Pharmacology provides her insights on fostering a positive work environment.

View Articles

Promising Results for Zilebesiran in Phase 1 Study

29
September 2023

We are pleased to share the findings from our recent Phase 1 study, which investigated the potential of Zilebesiran, an investigational RNA interference therapeutic.

View Articles

Engaging Hearts and Hands: A Day of Volunteering at Arc Nursery

12
September 2023

Discover how Richmond's dedicated team of volunteers is making a positive impact on young minds at Arc Nursery

View Articles

Exciting Research Update: Enhancing Blinding in Clinical Trials with Auto-Injectors

5
September 2023

We’re excited to share the findings of our recent study on the use of auto-injector systems (A-INJ) in randomized controlled trials (RCTs) by Dr Jorg Taubel, Dr Ulrike Lorch, Dr Thomas York and Vishal Aggarwal.

View Articles

Latest news

Regulatory Pathways to Success

January 9, 2026
Structured pathways to accelerate development and approval.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event